News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
549,969 Results
Type
Article (36924)
Company Profile (50)
Press Release (512989)
Multimedia
Podcasts (158)
Webinars (20)
Section
Business (156821)
Career Advice (2005)
Deals (24576)
Drug Delivery (118)
Drug Development (60599)
Employer Resources (129)
FDA (13073)
Job Trends (11863)
News (260797)
Policy (25539)
Tag
2027 BioCapital Standard (1)
2027 BioMidwest Elite (1)
2027 Bio NC Standard (1)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (2)
2027 Genetown Standard (4)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2440)
Academic (2)
Accelerated approval (45)
ADA (36)
Adcomms (23)
Allergies (164)
Alliances (42369)
ALS (187)
Alzheimer's disease (1497)
Antibody-drug conjugate (ADC) (455)
Approvals (13616)
Artificial intelligence (649)
ASCO (273)
Autoimmune disease (286)
Automation (47)
Bankruptcy (229)
Best Places to Work (9519)
BIO (53)
BIOSECURE Act (19)
Biosimilars (194)
Biotechnology (42)
Bladder cancer (184)
Brain cancer (69)
Breast cancer (854)
Cancer (5708)
Cardiovascular disease (393)
Career advice (1728)
Career pathing (46)
CAR-T (270)
CDC (54)
Celiac Disease (2)
Cell therapy (787)
Cervical cancer (52)
Clinical research (53528)
Collaboration (1967)
Commercialization (1)
Company closure (3)
Compensation (545)
Complete response letters (54)
COVID-19 (2313)
CRISPR (89)
C-suite (913)
Cystic fibrosis (117)
Data (7477)
Decentralized trials (3)
Denatured (53)
Depression (139)
Dermatology (78)
Diabetes (534)
Diagnostics (5594)
Digital health (58)
Diversity (9)
Diversity, equity & inclusion (34)
Drug discovery (312)
Drug pricing (188)
Drug shortages (27)
Duchenne muscular dystrophy (262)
Earnings (70892)
Editorial (62)
Employer branding (15)
Employer resources (118)
Events (80625)
Executive appointments (845)
FDA (16568)
Fibrodysplasia Ossificans Progressiva (10)
Friedreich's ataxia (18)
Frontotemporal dementia (32)
Funding (1492)
Gene editing (184)
Generative AI (60)
Gene therapy (615)
GLP-1 (845)
Government (4252)
Grass and pollen (6)
Guidances (398)
Healthcare (15823)
Hematology (148)
HIV (86)
Huntington's disease (43)
Idiopathic pulmonary fibrosis (1)
IgA nephropathy (90)
Immunology and inflammation (215)
Immuno-oncology (96)
Indications (192)
Infectious disease (2612)
Inflammatory bowel disease (241)
Inflation Reduction Act (13)
Influenza (115)
Intellectual property (275)
Interviews (362)
IPO (11676)
IRA (42)
Job creations (2634)
Job search strategy (1414)
JPM (53)
Kidney cancer (17)
Labor market (96)
Layoffs (371)
Leadership (41)
Legal (5864)
Liver cancer (79)
Longevity (28)
Lung cancer (747)
Lymphoma (419)
Machine learning (57)
Management (47)
Manufacturing (960)
Marketing (3)
MASH (176)
Medical affairs (1)
Medical device (10975)
Medtech (11115)
Mergers & acquisitions (14029)
Metabolic disorders (1303)
mRNA (187)
Multiple sclerosis (174)
NASH (11)
Neurodegenerative disease (355)
Neuropsychiatric disorders (75)
Neuroscience (2770)
Neurotech (1)
NextGen: Class of 2026 (5426)
Non-profit (4397)
Now hiring (42)
Obesity (570)
Opinion (274)
Ovarian cancer (214)
Pain (239)
Pancreatic cancer (304)
Parkinson's disease (310)
Partnered (28)
Patents (541)
Patient recruitment (599)
Peanut (50)
People (43016)
Pharmaceutical (14)
Pharmacy benefit managers (30)
Phase 1 (16347)
Phase 2 (23164)
Phase 3 (18423)
Pipeline (8748)
Policy (293)
Postmarket research (2138)
Preclinical (7123)
Press Release (50)
Prostate cancer (319)
Psychedelics (40)
Radiopharmaceuticals (282)
Rare diseases (949)
Real estate (4332)
Recruiting (55)
Regulatory (20349)
Reports (45)
Research institute (2203)
Resumes & cover letters (313)
Rett syndrome (43)
RNA editing (19)
RSV (71)
Schizophrenia (136)
Series A (232)
Series B (160)
Service/supplier (4)
Sickle cell disease (100)
Special edition (22)
Spinal muscular atrophy (130)
Sponsored (43)
Startups (2278)
State (1)
Stomach cancer (17)
Supply chain (106)
Tariffs (79)
The Weekly (104)
Vaccines (991)
Venture capital (91)
Weight loss (362)
Women's health (119)
Worklife (18)
Date
Today (110)
Last 7 days (417)
Last 30 days (1952)
Last 365 days (24588)
2026 (13088)
2025 (24445)
2024 (27459)
2023 (30950)
2022 (40636)
2021 (43623)
2020 (42703)
2019 (37405)
2018 (28072)
2017 (25038)
2016 (24268)
2015 (28043)
2014 (22720)
2013 (19377)
2012 (19855)
2011 (19878)
2010 (18428)
Location
Africa (757)
Alabama (80)
Alaska (7)
Arizona (232)
Arkansas (12)
Asia (32325)
Australia (5486)
California (10518)
Canada (3274)
China (1318)
Colorado (488)
Connecticut (531)
Delaware (337)
Europe (72620)
Florida (1783)
Georgia (402)
Hawaii (1)
Idaho (43)
Illinois (955)
India (82)
Indiana (542)
Iowa (17)
Japan (494)
Kansas (107)
Kentucky (38)
Louisiana (45)
Maine (68)
Maryland (1379)
Massachusetts (7431)
Michigan (339)
Minnesota (549)
Mississippi (6)
Missouri (139)
Montana (32)
Nebraska (18)
Nevada (122)
New Hampshire (65)
New Jersey (3134)
New Mexico (23)
New York (3045)
North Carolina (1371)
North Dakota (9)
Northern California (5178)
Ohio (318)
Oklahoma (19)
Oregon (32)
Pennsylvania (2228)
Puerto Rico (27)
Rhode Island (38)
South America (1007)
South Carolina (52)
South Dakota (2)
Southern California (4349)
Tennessee (201)
Texas (1908)
United States (38903)
Utah (341)
Vermont (2)
Virginia (307)
Washington D.C. (66)
Washington State (926)
West Virginia (3)
Wisconsin (97)
Wyoming (2)
549,969 Results for "national surgical adjuvant breast and bowel project nsabp".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
AccuStem Sciences Announces StemPrintER Pilot Study with National Surgical Adjuvant Breast and Bowel Project (NSABP)
January 8, 2026
·
4 min read
Press Releases
Exact Sciences, the NSABP Foundation, and the German Breast Group Present Results for the Oncodetect® MRD Test in Early Triple-Negative Breast Cancer at SABCS
December 12, 2025
·
6 min read
Press Releases
Genomic Profiling With MammaPrint + BluePrint Predicts Anthracycline Chemotherapy Benefit and Guides Personalized Treatment Selection in HR+HER2- Early-Stage Breast Cancer
June 25, 2026
·
5 min read
Approvals
Gilead’s TROP-2 Trodelvy, Keytruda combo win first-line FDA nods for breast cancer
Gilead’s Trodelvy can now be used as a monotherapy and in combination with Merck’s Keytruda to treat certain patients with triple-negative breast cancer.
June 25, 2026
·
1 min read
·
Tristan Manalac
Press Releases
Cairn Surgical Reports Pivotal Trial Results for Its Breast Cancer Locator System
May 4, 2026
·
3 min read
Breast cancer
AstraZeneca’s breast cancer pill hit with review delay after negative adcomm vote
An FDA advisory committee recently voted against approving AstraZeneca’s oral SERD drug camizestrant for certain patients with advanced breast cancer. It is unclear when the new target action date for the drug will be.
May 27, 2026
·
4 min read
·
Tristan Manalac
Press Releases
Personalis Secures Fourth Medicare Coverage Decision for NeXT Personal®, Expanding Breast Cancer Coverage to Pre-Surgical Treatment Monitoring
May 20, 2026
·
5 min read
Press Releases
Breathe BioMedical Expands Multi-Center Clinical Study in Breast Cancer to Pittsburgh
Weinstein Imaging Associates joins as clinical site to collect breath samples to advance development of a breath test for early detection of breast cancer in women
May 5, 2026
·
5 min read
Breast cancer
Celcuity slides even after ‘practice-changing’ late-stage breast cancer data
Celcuity’s gedatolisib doubled progression-free survival versus standard of care in certain patients with advanced breast cancer. Still, the biotech’s stock dropped more than 25% Tuesday.
June 3, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Phase III PALLAS Study Shows Signatera™ MRD Testing Provides Powerful Post‑Surgical Prognostic Information in Patients with High and Intermediate Risk HR+/HER2‑ Breast Cancer
December 11, 2025
·
6 min read
1 of 54,997
Next
